Baidu
map

CDS 2015:纪立农:糖尿病的诊断和筛查指标--血糖还是糖化血红蛋白?

2015-12-14 MedSci MedSci原创

在2015CDS年会上,来自北京大学人民医院的纪立农教授分享了《糖尿病的诊断和筛查指标--血糖还是糖化血红蛋白》的议题,纪立农教授指出,基于群体研究中血糖和基于糖化血红蛋白的糖尿病诊断方法各自有优缺点和适用的人群特异性,建立在大规模前瞻性队列的糖尿病自然病程研究才是实现精准诊断糖尿病的必经之路。 2010年流行病学研究--血糖和HbA1c诊断糖尿病的差异 在2007年-2008年的大型流行病学

在2015CDS年会上,来自北京大学人民医院的纪立农教授分享了《糖尿病的诊断和筛查指标--血糖还是糖化血红蛋白》的议题,纪立农教授指出,基于群体研究中血糖和基于糖化血红蛋白的糖尿病诊断方法各自有优缺点和适用的人群特异性,建立在大规模前瞻性队列的糖尿病自然病程研究才是实现精准诊断糖尿病的必经之路。

2010年流行病学研究--血糖和HbA1c诊断糖尿病的差异

在2007年-2008年的大型流行病学调查中,采用血糖为诊断指标的糖尿病患病率为9.7%,糖尿病前期患病率为15.5%;而在2010年的流行病学调查中,在采用血糖为诊断指标的同时采用HbA1c进行诊断,糖尿病患病率为11.6%,糖尿病前期的患病率为50.1%。

在社区的高危人群中,采用HbA1c≥6.5%为诊断指标,糖尿病的患病率为6.5%,而采用OGTT为诊断指标的,患病率为11.1%;在医院的高危人群中,采用HbA1c≥6.5%为诊断指标,糖尿病的患病率为29.1%,而采用OGTT为诊断指标的,患病率为46.2%。采用两种指标诊断和筛查糖尿病的结果差异很大。


图1

在来自Effects of diabetes definition on global surveillance of doabetes prevalence and diagnosis: a pooled analysisi of 96 population-based studies with 331,288 partipants的研究中,仅采用HbA1c诊断糖尿病的患病率要高于仅采用OGTT诊断糖尿病的患病率。

基于血糖的糖尿病诊断标准

血糖诊断糖尿病的切点,空腹和2小时血糖与视网膜病变的相关性,当两者大于诊断切点时,视网膜病变的繁盛风险上升。来自北京平谷的研究显示,HbA1c、空腹血糖与视网膜病变发生风险增加。

OGTT与糖化血红蛋白筛查和诊断糖尿病的优缺点

OGTT的优点是诊断的“金标准”,与并发症发生的风险相关;缺点是需要空腹,耗费时间长,生物变异性大,空腹与2h血糖缺乏一致性。

基于HbA1c的糖尿病诊断标准

糖化血红蛋白筛查的优点有不需要空腹,节省时间,日间变异性低,与并发症发生的风险相关(流行病学、RCT研究)。2009年国际专家委员会建议将HbA1c≥6.5%做为糖尿病的诊断指标,随后2010年ADA,2011年WHO采纳该建议。在南亚人群采用HbA1c做为糖尿病诊断标准可增加糖尿病或糖尿病前期的患病率,南亚人群中HbA1c的增高与缺铁性贫血指标相关。

最后,纪立农教授总结了以下几点:

基于群体研究中血糖和HbA1c的糖尿病诊断切点分别根据血糖或HbA1c与视网膜病变的相关性而独立获得,缺乏个体精准性;

符合血糖和HbA1c的糖尿病诊断切点的糖尿病患者仅有部分重叠,部分患者仅满足血糖或HbA1c的糖尿病诊断切点;

缺铁性贫血或缺铁状态是导致HbA1c与血糖分离的主要原因;

符合血糖或HbA1c的糖尿病诊断切点的部分个体仅轻度非进展性血糖增高,这些个体并发症发生风险非常低,在目前的血糖诊断体系下被“误诊”为糖尿病;

基于群体研究中血糖和基于HbA1c的糖尿病诊断方法各自有优缺点和适用的人群特异性;

建立在大规模前瞻性队列的糖尿病自然病程研究是实现精准诊断糖尿病的必经之路。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2016-05-19 bshuang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-27 wzf990214

    有意思

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-27 wzf990214

    赞一个

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-21 qingfengqishi5

    收藏了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-16 智智灵药
  7. [GetPortalCommentsPageByObjectIdResponse(id=2077971, encodeId=bbe920e79712a, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Thu May 19 07:17:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49497, encodeId=56b34949ef2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49498, encodeId=62e849498c5, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 18:57:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48389, encodeId=bb4c4838977, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:55:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46928, encodeId=88a24692875, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Dec 21 07:35:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377594, encodeId=aa8c13e759403, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 16 06:17:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46116, encodeId=42534611623, content=为什么不用国际标准?, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 14 18:17:00 CST 2015, time=2015-12-14, status=1, ipAttribution=)]
    2015-12-14 lovetcm

    为什么不用国际标准?

    0

相关资讯

CDS2015:两项真实世界的糖尿病研究结果发布

1.IntroDia研究对我国糖尿病管理的启示 作者:北京大学人民医院纪立农 糖尿病患者确诊后首次接触医生以及在之后就诊过程中会面临很多问题。IntroDia研究即2型糖尿病患者早期对话研究是首次探讨在更好地管理、控制糖尿病过程中,非药物因素所起作用的研究。该研究于2013年12月2日启动,为迄今全球最大规模的糖尿病跨国统计调查,将纳入逾万例自报和确诊的2型糖尿病患者,涉及26个国家650

AIM:GLP-1RAs治疗2型糖尿病—受益和损害

与其他每周一次GLP-1RAs相比,dulaglutide (1.5mg)、每周一次exenatide和taspoglutide(20mg)具有较大程度降低HbA1c、空腹血糖和体重的效果。Taspoglutide (20mg)使用者发生恶心的风险最高。每周一次GLP-1RAs类药物使用者发生低血糖的风险相似。

Diabetes Care:生活方式干预帮助孕期糖尿病女性达到减重目标!

妊娠期糖尿病女性在分娩以后患上2型糖尿病风险高达7倍!超过75%的为少数名族!超重和肥胖也是导致2型糖尿病的危险因素。目前有研究探究基于健康系统的方式帮助孕期糖尿病女性在分娩后1年内达到减重目标。该研究对通过邮件和电话指导对1087名女性进行生活方式干预。一共有1193名女性收到了关于糖尿病风险及预防的印刷材料。孕期糖尿病女性在分娩后6个月内接受干预指导减重达到目标的可能性比常规照顾女性高45%(

IDF 2015:全世界共有4.15亿成年人患有糖尿病,中国1.1亿人

根据国际糖尿病联盟(IDF)12月1日在“2015年世界糖尿病大会”上最新发布的第7版糖尿病概览(Diabetes Atlas)(点击下载全文),世界范围内共有4.15亿成年人患有糖尿病,即每11人中便有1人患有糖尿病。该最新版结合了糖尿病类型,显示自从2013年发布的上版概览以来,全世界共增加了3.1千万的成年糖尿病患者。发病率和患病率12月1日,美国糖尿病控制与预防中心发布的最新数据表明,美国

CDS 2015:翁建平谈中国近20年糖尿病领域研究带给我们的启示

从1985年兰州会议开始,中国糖尿病学术界已经开始着手应对糖尿病患者的快速增长甚至大流行的问题。中国社会面临严重的医疗资源和经济负担的挑战:人均GDP 5000美元是非传染性疾病加速流行的拐点,也是提供基本医疗保障的拐点。糖尿病及其并发症与生活方式密切相关,在现实生活中可以预防;也必须进行预防,否则后果不堪设想。从结构上看,中国糖尿病领域一直存在重治疗,轻预防;重治疗,轻管理;重2型,轻1型;重医

CDS 2015:洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用

北京大学第三医院内分泌科 洪天配教授 二肽基肽酶4(DPP-4)抑制剂与钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂是两类新型降糖药物。研究显示,DPP-4酶抑制剂可通过直接作用于肾脏而发挥潜在的肾脏保护作用,而SGLT-2抑制剂则可通过改善肾小球高滤过状态而发挥肾脏保护作用。 本讲座主要从DPP-4酶抑制剂和SGLT-2抑制剂的作用机制、在肾损伤患者中的药代动力学、基础和临床研究相关

Baidu
map
Baidu
map
Baidu
map